TE
$1.14
+0.00
(0.00%)
As of Oct 5, 2026, 5:11 PM EDT
Price history
TELA Bio (TELA) is trading up at $1.14 (0.00%), as of the latest quote. It operates in the Health Care sector.
IPO: November 8, 2019 · $13.00 offering · NASDAQ · View IPO details →
TELA Bio revenue & net income history (FY2017–FY2025)
RevenueNet income
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $4.25M | $8.27M | $15.4M | $18.2M | $29.5M | $41.4M | $58.5M | $69.3M | $80.3M |
| Growth (year over year) | — | +94.9% | +86.7% | +17.9% | +61.8% | +40.6% | +41.1% | +18.6% | +15.8% |
| Gross profit | $2.53M | $2.94M | $9.27M | $11.2M | $18.8M | $27.0M | $40.1M | $46.5M | $54.3M |
| Gross margin | 59.6% | 35.6% | 60.0% | 61.7% | 63.9% | 65.3% | 68.6% | 67.1% | 67.7% |
| Operating income | −$16.9M | −$17.8M | −$19.2M | −$25.3M | −$29.5M | −$39.0M | −$44.1M | −$34.1M | −$33.8M |
| Operating margin | −398.7% | −214.9% | −124.1% | −138.8% | −100.0% | −94.2% | −75.4% | −49.2% | −42.0% |
| Net income | −$21.3M | −$21.1M | −$22.4M | −$28.8M | −$33.3M | −$44.3M | −$46.7M | −$37.8M | −$38.8M |
| Net margin | −502.6% | −254.9% | −145.2% | −158.1% | −112.9% | −106.9% | −79.8% | −54.6% | −48.4% |
| EPS (diluted) | — | −$101.41 | −$17.10 | −$2.23 | −$2.30 | −$2.72 | −$2.04 | −$1.33 | −$0.83 |
| Balance sheet | |||||||||
| Cash and equivalents | $11.3M | $17.3M | $45.3M | $74.4M | $43.9M | $42.0M | $46.7M | $52.7M | $50.8M |
| Total assets | — | $27.2M | $67.9M | $86.5M | $62.5M | $67.9M | $78.0M | $86.6M | $81.4M |
| Total liabilities | — | $40.9M | $37.0M | $37.4M | $42.4M | $53.5M | $59.2M | $58.1M | $75.1M |
| Long-term debt | — | — | $30.2M | $30.8M | $31.5M | $39.9M | $40.5M | $41.1M | $55.7M |
| Shareholders' equity | −$108.2M | −$137.9M | $31.0M | $49.0M | $20.1M | $14.3M | $18.9M | $28.5M | $6.31M |
| Cash flow | |||||||||
| Operating cash flow | −$16.4M | −$19.9M | −$25.5M | −$24.5M | −$30.4M | −$40.7M | −$40.9M | −$41.6M | −$28.2M |
| Capital expenditure | $114.0K | $62.0K | $197.0K | $167.0K | $627.0K | $872.0K | $611.0K | $989.0K | $448.0K |
| Free cash flow | −$16.5M | −$20.0M | −$25.7M | −$24.6M | −$31.1M | −$41.6M | −$41.5M | −$42.6M | −$28.7M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $19.0M | $17.6M | $18.5M | $20.2M | $20.7M | $20.9M | $19.1M | $19.3M |
| Growth (year over year) | +25.9% | +3.8% | +11.5% | +25.5% | +9.1% | +18.2% | +2.9% | −4.5% |
| Gross profit | $12.9M | $11.2M | $12.5M | $14.1M | $14.0M | $13.8M | $12.5M | $13.9M |
| Gross margin | 67.8% | 63.6% | 67.6% | 69.8% | 67.5% | 65.9% | 65.7% | 72.3% |
| Operating income | −$9.37M | −$8.35M | −$10.5M | −$9.08M | −$7.55M | −$6.65M | −$10.5M | −$9.28M |
| Operating margin | −49.4% | −47.3% | −56.5% | −45.0% | −36.5% | −31.9% | −55.2% | −48.1% |
| Net income | −$10.4M | −$9.21M | −$11.3M | −$9.92M | −$8.60M | −$9.04M | −$12.3M | −$11.3M |
| Net margin | −54.7% | −52.2% | −60.8% | −49.1% | −41.6% | −43.3% | −64.4% | −58.4% |
| EPS (diluted) | −$0.42 | −$0.17 | −$0.25 | −$0.22 | −$0.19 | −$0.17 | −$0.21 | −$0.20 |
| Balance sheet | ||||||||
| Cash and equivalents | $17.3M | $52.7M | $42.8M | $35.0M | $29.7M | $50.8M | $39.5M | $30.4M |
| Total assets | $53.0M | $86.6M | $77.3M | $67.5M | $61.6M | $81.4M | $69.9M | $59.7M |
| Total liabilities | $59.3M | $58.1M | $59.1M | $58.4M | $60.0M | $75.1M | $75.1M | $75.6M |
| Long-term debt | $41.0M | $41.1M | $41.3M | $38.1M | $41.5M | $55.7M | $55.9M | $56.1M |
| Shareholders' equity | −$6.27M | $28.5M | $18.1M | $9.18M | $1.56M | $6.31M | −$5.20M | −$15.9M |
| Cash flow | ||||||||
| Operating cash flow | −$8.98M | −$7.53M | −$9.72M | −$7.91M | −$5.72M | −$4.87M | −$11.2M | −$9.38M |
| Capital expenditure | $122.0K | $264.0K | $32.0K | $114.0K | $211.0K | $91.0K | $119.0K | $59.0K |
| Free cash flow | −$9.11M | −$7.79M | −$9.76M | −$8.02M | −$5.93M | −$4.96M | −$11.3M | −$9.44M |
From TELA Bio's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About TELA Bio
- Headquarters
- Malvern, Pennsylvania From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with TELA
- TCMD Tactile Systems Technology Inc
- TCRX TScan Therapeutics
- TDOC Teladoc Health Inc
- TECX Tectonic Therapeutic Inc
- TEM Tempus AI
- TENX Tenax Therapeutics
- TFX Teleflex
- TGTX Tg Therapeutics Inc